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Endovascular Intervention for Renal Artery Stenosis in
Renal Transplant
Philip C.H. Kwok
Renal artery stenosis occurs in 1% to 16% of adult renal transplant recipients. Revascularization improves
renal function and leads to better blood pressure control. Angioplasty is usually attempted first. A vascular
stent is used if there are complications with angioplasty or if there is recurrent stenosis after repeated angioplasty.
Complications of angioplasty or stent insertion, though rare, may have severe consequences and lead to graft
loss. In-stent restenosis is a major concern with the use of vascular stents. [Hong Kong J Nephrol 2003;5(2):
73–7]
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INTRODUCTION
Renal artery stenosis (RAS) occurs in 1% to 16% of
adults after renal transplant, depending on the
diagnostic cri teria used and indications for
ar ter iography [1–7] .  The  in terval  be tween
transplantation and diagnosis of transplant RAS ranges
from 2 to 45 months (range of mean, 10–21 months)
[6]. Different etiologic factors have been postulated,
including faulty surgical technique, postoperative
periarterial fibrosis, immune response, cytomegalovirus
infection, long cold ischemia time, atherosclerosis,
trauma, and chronic rejection [4,7–16]. The etiologies
are mostly different from those causing RAS in native
kidneys.
RAS is important in renal transplant because it
occurs in a solitary kidney, which is precious to the
patient. Prolonged RAS may cause renal ischemia,
leading to hypertension and uremia. Revascularization
will improve renal function and lead to better blood
pressure control [8,17]. RAS should be suspected if
there is worsening renal function, problems with blood
pressure control, or progressive deterioration in these
parameters. Non-invasive imaging methods should be
used to confirm or exclude the diagnosis. The most
commonly used modality is ultrasound with Doppler
study. Contrast-enhanced magnetic resonance
angiography (CE-MRA) and computed tomography
angiography (CTA) are usually used to confirm RAS
diagnosed by Doppler ultrasound. CE-MRA and CTA
can produce three-dimensional images that provide
information on the orientation of the arteries, which is
important in choosing the correct plane of projection
during subsequent intervention.
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TREATMENT OPTIONS
Even when RAS is diagnosed, not all patients will
immediately undergo angioplasty or surgery. RAS can
be managed with antihypertensive drugs. The risk of
vascular injury and loss of the graft kidney during
angioplasty or surgery must be balanced against the
benefit of revascularization. There is no hard and fast
rule in this, but the severity of impairment, difficulty
in blood pressure control, and rapidity of worsening
function may provide the best indications for
intervention.
One may choose either surgical means or
endovascular means of revascularization. There is no
randomized control trial comparing the results of
endovascular intervention and surgery. Each method
has its own advocates. Surgery was favored in the late
1980s and early 1990s, when one study showed that
the immediate success rate with surgical repair (SR)
was 92.1%, compared with 69% with percutaneous
transluminal angioplasty (PTA) [18]. The long-term
success rate was 81.5% with SR and 40.8% with PTA,
with a mean follow-up period of 56.7 months and 32
months, respectively. It is outside the scope of this paper
to discuss techniques of surgical revascularization. Most
practitioners will choose endovascular means as the first
line of intervention due to its technical effectiveness
and better tolerance by patients. It also does not preclude
subsequent surgical correction if required.
RAS can occur in different anatomic locations. It is
mostly seen in the arterial anastomosis between the graft
renal artery and the recipient artery. It may also be seen
along the main renal artery or in the intrarenal branches.
Occasionally, arterial stenosis is present in the external
iliac artery or internal iliac artery of the recipient, which
may produce similar clinical pictures. Another variant
is vascular kinking.
PROCEDURE
Anastomotic strictures and strictures in the main renal
artery may be treated using balloon angioplasty
supplemented with vascular stenting, if necessary.
Intrarenal stricture may need to be treated according to
the etiology, since graft rejection may produce multiple
strictures in the intrarenal branches, and the clinical
course may not be changed by PTA. Stenosis in the
iliac arteries may be treated using angioplasty or
stenting, but one should be careful not to occlude the
orifice of the renal artery if the graft is anastomosed to
the external iliac artery and the stricture is just adjacent
to the anastomosis. Functionally significant vascular
kinking is better treated by surgical means [19].
The stricture is often approached from the common
femoral artery. If the anastomosis is in the internal iliac
artery, one usually approaches from the contralateral
femoral artery. If the anastomosis is in the external iliac
artery, one may approach from either the ipsilateral or
contralateral femoral artery, depending on the
configuration of the anastomosis. The stenosis is
confirmed through a femoral arterial sheath and
diagnostic catheter. Non-ionic contrast medium is now
used routinely to minimize contrast nephrotoxicity. If
the patient has severely impaired renal function, a dimer
contrast agent may be used, as it is iso-osmolar with
blood and is, theoretically, less nephrotoxic [20,21].
Recently, carbon dioxide- and gadolinium-based
contrast have been used for angiography (Figure 1).
Carbon dioxide provides negative contrast and
gadolinium-based agents are primarily used in magnetic
resonance imaging. Both types of contrast media are
much less nephrotoxic than iodine-based contrast, but
the contrast resolution is not as good [22–27].
Before angioplasty, we give at least 5,000 units of
heparin for systemic anticoagulation; 0.2 mg intra-
arterial nitroglycerin is also given to the distal renal
branch to prevent arterial spasm. The stenosis is
traversed with a guidewire and a balloon catheter is
used to dilate the stricture. The diameter of the balloon
used is about 10% larger than the diameter of the artery,
which is measured using calibration software in the
angiography equipment. The intra-arterial pressure
gradient across the stricture is measured after
angioplasty. If the residual stenosis is less than 30%,
or the pressure gradient across the stricture is less than
15 mmHg, we may stop and follow up the patient
(Figure 2). If both parameters are unsatisfactory, one
may consider implantation of a renal stent.
A renal stent is also indicated if there are angioplasty
complications, such as arterial dissection, or if there is
recurrent stenosis after repeated angioplasty. For renal
stenting, a balloon-expandable stent is usually used. A
very short stent can be deployed in this way and the
placement is precise. The newer generation of stents
have a lower profile and cross the curves and angles
quite readily with the use of a guiding catheter. The
stent is deployed across the stricture under continual
angiographic guidance, and the final result is confirmed
using angiography. A stent will usually produce an
immediate satisfactory result. If stricture is due to very
resistant fibrosis, the stent may be compressed by the
elastic force and the vascular lumen will not be fully
opened.
COMPLICATIONS
Immediate complications of PTA are uncommon, and
include arterial dissection, rupture, guidewire-induced
vasospasm, and graft loss. A dissection may be treated
with a renal stent; however, if the dissection is
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extensive, the graft may not be salvageable. A covered
stent may be used for arterial rupture. In severe
hemorrhage, emergency surgery may be necessary to
salvage the kidney. Guidewire-induced spasm is usually
relieved after the guidewire is withdrawn. If it is not,
renal ischemia may have occurred due to unperfused
renal parenchyma. Death related to the procedure has
been reported, although it is rare. Other remote
complications, such as postoperative myocardial
infarction and complications related to the use of
Figure 1. Carbon dioxide angiography (A) can provide similar information to iodinated contrast angiography (B), except that there is
more noise in the carbon dioxide angiogram, which is due to the lower contrast resolution.
A B
Figure 2. A tight renal artery stenosis (A) dilated with a 6 mm balloon, resulting in residual stenosis and a systolic pressure gradient of
37 mmHg (B). Even with implantation of a 6 mm metallic stent, the stricture is not fully expanded (arrow), probably due to periarterial
fibrosis. The systolic pressure gradient becomes 13 mmHg, and the clinical response is satisfactory (C).
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heparin, are possible [28]. Early postoperative
complications of angioplasty and stent implantation
include the risk of early arterial thrombosis. Therefore,
oral aspirin for at least 6 months and clopidogrel for 1
month are recommended. Cholesterol embolization is
less likely after PTA and stenting in the renal graft since
the etiology of the stricture is different from that of
RAS in native kidneys. The major late complication of
PTA is restenosis, which usually appears 6 to 8 months
after angioplasty [13], and which is usually the result
of intimal hyperplasia. In-stent restenosis also occurs
after stent placement.
OUTCOME
Though there are many medical reports that discuss
this topic, nearly all are limited by their retrospective
nature and the small number of patients involved. The
reporting format is also different. In a French study of
195 PTAs in 151 patients with graft RAS, the initial
success rate was 85%. There was 30% restenosis, and
the restenosis rate after repeated PTA was 26%. The 5-
year secondary patency rate was more than 85% [29].
In other papers with small study populations, technical
success rates ranged from 81% to 94% [16,28,30], and
clinical success rates ranged from 67% to 82% [10,16,
30]. In segmental branches, there is a lower success
rate (67%); the primary patency is 58% and the
secondary patency is 69% at a mean follow-up of 5.1
years [28]. The success rate is lower for anastomotic
strictures [13]. Though the incidence of stenosis is
similar between end-to-side anastomosis to the external
iliac artery and end-to-end anastomosis to the internal
iliac artery, PTA in the latter situation is technically
more difficult and results in a higher complication rate
and more graft loss [6].
It is very tempting to implant a renal stent to provide
a good final picture before the patient leaves the
angiographic suite. However, both the clinician and
patient should understand the risk of late restenosis.
There is no large series that identifies late restenosis in
stents used in renal transplant. The number of patients
receiving stents for RAS in renal graft is usually small
and the studies are all retrospective. In a study involving
seven patients followed for a median of 14.8 months,
five remained normal and there were two with
insignificant restenosis (< 35% and 50%). All had good
blood pressure control [13]. In another six patients with
a mean follow-up of 34 months, all stents were patent
and there was one restenosis of less than 50% with no
clinical significance [31]. Bertoni et al reported their
results using Palmaz stents in nine patients followed
for 1 to 3 years. There were significant drops in
mean blood pressure and peak flow velocity in the
renal artery, but no significant changes in serum
creatinine [32].
One may get an idea of the long-term results of
stenting by referring to the results with stents in native
kidneys. A meta-analysis by Rees reported a 99%
technical success rate after stent placement in 1,128
arteries [33]. Follow-up angiography of 563 arteries
performed at a mean of 7.9 months showed 77%
patency. Leertouwer et al showed 26% restenosis
angiographically in 236 arteries at a mean follow-up
of 19 months [34], which is not significantly better than
the 30% restenosis after PTA in 515 patients reported
by Rees. Though late restenosis may be treated using
re-angioplasty, we are dealing with a solitary kidney
and an unnecessary stent may mean a long nightmare
for the patient. Thus, our policy is to try angioplasty
first. If the result is radiologically less than satisfactory,
but the pressure gradient is less than 15 mmHg, we
follow the patient clinically, assess the blood pressure,
and determine whether the dosage of antihypertensive
drugs can be reduced or if there is any improvement in
renal function. If the clinical response is not good, it
may not be too late to intervene again.
Stent technology is always evolving, and there is
continuing research and development to prevent
restenosis after stenting. A recent promising technique
involves drug-eluting stents. A sirolimus-coated stent
has proven to be effective in preventing restenosis after
stenting in coronary arteries and femoral arteries [35,
36]. Its use in the renal artery is still in the early
experimental period, but if drug-eluting stents can be
shown to reduce restenosis, it will be a milestone in
endovascular intervention for renal transplantation.
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